[9] However, several studies have identified mutations in tumor suppressor genes, including TP53 and RB1, and p16 expression has been implicated as a robust immunohistochemical marker for these tumors [10,11,12,13,14,15,16,17,18,19]. This evidence concerns the gene TP53 and neoplasm.